Where is Empiriko located?

Empiriko is headquartered in Newton, United States.

Is Empiriko a funded company?

Empiriko is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Empiriko rank among its competitors?

Empiriko ranks 667th amongst 696 active competitors, of which 231 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Empiriko?

Empiriko's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Empiriko - 2026 Company Profile, Team, Funding & Competitors

Empiriko is a funded company based in Newton (United States), founded in 2010 by Pam Randhawa. It operates as a Biotech revolutionizing cancer treatment with targeted therapies and advanced diagnostics. The company has 696 active competitors, including 231 funded and 144 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

Biotech revolutionizing cancer treatment with targeted therapies and advanced diagnostics. The company focuses on developing innovative radioligand therapies and antibody drug conjugates for cancer, alongside next-generation point-of-care diagnostics. Their integrated technologies leverage medicinal chemistry, immunology, engineering, and computational modeling to connect drug delivery platforms with disease/drug monitoring devices. This synergistic approach aims to revolutionize personalized care and improve patient outcomes cost-effectively. The company's targeted drug delivery system offers a scalable platform for delivering therapies to cellular targets throughout the body, while their remote monitoring device provides real-time disease and drug response analysis. This data-driven approach accelerates drug development, expands patient access, and customizes treatment for improved clinical results. They are focused on precision medicine, healthcare, life sciences, drug discovery, and personalized diagnostics.

Website: www.empiriko.com/
Email ID: *****@empiriko.com

Key Metrics

Founded Year

2010

Location

Newton, United States

Stage

Funding Raised

Investors

C2I Accelerator

Ranked

667^th among 696 active competitors

Similar Companies

Alnylam & 897 more

View Empiriko's full profile

Empiriko is a funded company. Empiriko has 1 institutional investor.

View details of Empiriko's funding rounds and investors

The founders of Empiriko is Pam Randhawa.

Here are the details of Empiriko's key team members:

Pam Randhawa: Founder & CEO of Empiriko.

View details of Empiriko's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Empiriko include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of Empiriko, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
667th	Empiriko 2010, Newton (United States), Funding Raised	Biotech revolutionizing cancer treatment with targeted therapies and advanced diagnostics	-	C2I Accelerator	21/100